$19.58
arrow_drop_down3.97%Key Stats | |
---|---|
Open | $20.00 |
Prev. Close | $20.37 |
EPS | -2.33 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 18.94 | 21.09 |
52 Week Range | 17.27 | 45.00 |
Ratios | |
---|---|
EPS | -2.33 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
mRNA Cancer Vaccines and Therapeutics Research Report 2024 with Long-term Forecasts to 2028 and 2033: Personalized Medicine and Multivalent mRNA Vaccines Lead the Way
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses
Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
Does Arcturus Therapeutics Have the Potential to Rally 216.35% as Wall Street Analysts Expect?
Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates
Cystic Fibrosis Therapeutics Research Report 2024: A Global $15.42 Billion Market by 2032 from $7.07 Billion in 2023 ... - GlobeNewswire